Fortress Biotech, Inc.

NasdaqCM:FBIO Stock Report

Market Cap: US$71.0m

Fortress Biotech Management

Management criteria checks 2/4

Fortress Biotech's CEO is Lindsay Rosenwald, appointed in Dec 2013, has a tenure of 12.33 years. total yearly compensation is $1.38M, comprised of 4.5% salary and 95.5% bonuses, including company stock and options. directly owns 14.39% of the company’s shares, worth $10.22M. The average tenure of the management team and the board of directors is 7.6 years and 10.8 years respectively.

Key information

Lindsay Rosenwald

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage4.54%
CEO tenure12.3yrs
CEO ownership14.4%
Management average tenure7.6yrs
Board average tenure10.8yrs

Recent management updates

Recent updates

FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential

Analysts have adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around a fair value of $4.50, a discount rate of 8.80%, revenue growth of 44.56%, a profit margin of 12.79% and a future P/E of 9.24. Valuation Changes Fair Value: Maintained at $4.50, with no change in the estimated fair value per share.

FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential

Analysts have adjusted their price target on Fortress Biotech to reflect updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. This has led to a revised target that is intended to better align with the company’s current risk and earnings outlook.

FBIO: Menkes Disease Breakthrough And Voucher Will Drive Future Upside Potential

Analysts have modestly adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping the overall fair value view steady. What's in the News FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, marking the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).

FBIO: Menkes Disease Approval And Voucher Will Drive Future Upside Potential

Analysts have adjusted their price target on Fortress Biotech, maintaining it at $4.50, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions that continue to support a similar fair value estimate. What's in the News Fortress Biotech and majority owned subsidiary Cyprium Therapeutics received FDA approval for ZYCUBO (copper histidinate, formerly CUTX-101) to treat Menkes disease in pediatric patients, the first and only FDA approved treatment for this rare and often fatal condition (Key Developments).

FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Support Upside Potential

Analysts have modestly adjusted their price target on Fortress Biotech, reflecting updated views on revenue growth, profit margins, and future P/E assumptions, while keeping the underlying fair value estimate steady at $4.50. What's in the News The U.S. FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients.

Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap

Feb 20

FBIO: Menkes Disease Approval And Voucher Potential Will Drive Bullish Upside

Analysts have nudged their price target on Fortress Biotech higher to $4.50, reflecting updated assumptions around revenue growth, profit margins, and a slightly lower discount rate that together indicate a modestly stronger outlook for the company. What's in the News The U.S. Food and Drug Administration approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).

Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower

Feb 05
Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower

FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Drive Bullish Outlook

Analysts have adjusted their price target on Fortress Biotech, reflecting updated assumptions on a discount rate, a profit margin of 65.99% and a future P/E of 1.53x. They are tying the change to a revised view of the company’s earnings power and risk profile.

FBIO: Resubmitted Menkes Therapy And Voucher Potential Will Shape Balanced Outlook

Analysts have adjusted their price target on Fortress Biotech to US$4.50, with the update mainly tied to refreshed assumptions around the discount rate, revenue growth near 48.3%, profit margin around 16.2% and a future P/E of about 6.17x. What's in the News Fortress Biotech and majority-owned subsidiary Cyprium Therapeutics had the resubmission of the New Drug Application for CUTX-101, a copper histidinate therapy for pediatric Menkes disease, accepted by the U.S. FDA as a Class 1 resubmission, with a new PDUFA target action date of January 14, 2026 (company announcement).

FBIO: FDA Progress On Rare Disease Therapy Will Drive Significant Upside Potential

Analysts have modestly lifted their price target on Fortress Biotech to $4.50 per share, citing slightly lower perceived risk, marginally stronger long term revenue growth, and a small improvement in projected profitability that together support a higher justified valuation multiple. What's in the News FDA accepts resubmission of the New Drug Application for CUTX-101 for Menkes disease as a Class 1 resubmission, setting a new PDUFA target action date of January 14, 2026 (Key Developments) Earlier FDA Complete Response Letter for CUTX-101 cited cGMP compliance issues at the manufacturing site but raised no concerns with the drug's efficacy or safety data (Key Developments) Sentynl Therapeutics now holds full responsibility for development and commercialization of CUTX-101, with Cyprium eligible for royalties, up to $129 million in milestones, and a potential Rare Pediatric Disease Priority Review Voucher upon approval (Key Developments) CUTX-101 NDA, initially granted Priority Review, is supported by positive topline data showing significant improvement in overall survival in Menkes disease patients treated early (Key Developments) Valuation Changes Fair Value: unchanged at $4.50 per share, reflecting a stable central valuation despite minor model adjustments Discount Rate: decreased slightly from 8.36 percent to 8.07 percent, indicating a modest reduction in perceived risk Revenue Growth: increased slightly from 46.90 percent to 47.54 percent, reflecting marginally stronger long term growth expectations Net Profit Margin: increased slightly from 16.03 percent to 16.24 percent, pointing to a small improvement in projected profitability Future P/E: declined modestly from 6.51x to 6.29x, suggesting a slightly lower multiple applied to future earnings

Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump

Dec 16
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump

FBIO: Menkes Drug Clearance Of Manufacturing Issues Will Unlock Significant Upside Potential

Analysts have modestly raised their price target on Fortress Biotech to reflect a slightly higher fair value estimate of $4.50 per share, supported by expectations for stronger revenue growth and only a modest adjustment to discount rates and future valuation multiples. What's in the News The FDA issued a Complete Response Letter for the CUTX-101 New Drug Application for Menkes disease, citing cGMP deficiencies at the manufacturing facility but raising no concerns about efficacy or safety data.

Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive

Oct 05
Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive

FDA Approval Will Open $1 Billion Dermatology Market

Despite increased revenue growth forecasts, Fortress Biotech’s consensus price target was lowered from $10.00 to $8.00 amid a sharply reduced future P/E, indicating a more cautious outlook on profitability relative to anticipated sales growth. What's in the News Fortress Biotech was dropped from the Russell Microcap Growth Benchmark Index.

Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks

Aug 17
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks
User avatar

FDA Approval Will Open $1 Billion Dermatology Market

Emrosi's successful launch and growing market adoption are expected to drive significant revenue growth, improved operating leverage, and expanding net margins.

Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price

Mar 11
Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price

Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry

Oct 29
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry

Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

Jul 26
Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Aug 18
There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

CEO Compensation Analysis

How has Lindsay Rosenwald's remuneration changed compared to Fortress Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-US$2m

Sep 30 2025n/an/a

-US$5m

Jun 30 2025n/an/a

-US$24m

Mar 31 2025n/an/a

-US$51m

Dec 31 2024US$1mUS$63k

-US$56m

Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$49m

Mar 31 2024n/an/a

-US$63m

Dec 31 2023US$1mUS$63k

-US$69m

Sep 30 2023n/an/a

-US$86m

Jun 30 2023n/an/a

-US$104m

Mar 31 2023n/an/a

-US$100m

Dec 31 2022US$1mUS$63k

-US$95m

Sep 30 2022n/an/a

-US$97m

Jun 30 2022n/an/a

-US$93m

Mar 31 2022n/an/a

-US$74m

Dec 31 2021US$3mUS$60k

-US$65m

Sep 30 2021n/an/a

-US$38m

Jun 30 2021n/an/a

-US$33m

Mar 31 2021n/an/a

-US$43m

Dec 31 2020US$3mUS$59k

-US$47m

Sep 30 2020n/an/a

-US$57m

Jun 30 2020n/an/a

-US$54m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$1mUS$32k

-US$40m

Compensation vs Market: Lindsay's total compensation ($USD1.38M) is above average for companies of similar size in the US market ($USD618.13K).

Compensation vs Earnings: Lindsay's compensation has increased whilst the company is unprofitable.

CEO

Lindsay Rosenwald (70 yo)

12.3yrs
Tenure
US$1,380,197
Compensation

Dr. Lindsay Allan Rosenwald, M.D. serves as Director of Urica Therapeutics, Inc. He serves as Director at Caelum Biosciences, Inc. He serves as an Executive Chairman of Journey Medical Corporation since Oc...

Leadership Team

NamePositionTenureCompensationOwnership
Lindsay Rosenwald
Executive Chairman12.3yrsUS$1.38m14.39%
$ 10.2m
David Jin
CFO & Head of Corporate Development5.9yrsUS$2.33m0.067%
$ 47.6k
Xiaoqin Lu
Chief Strategy Officer1yrUS$40.03k0.016%
$ 11.5k
Michael Weiss
Executive Vice Chairman of Strategic Development & Director12.2yrsUS$1.23m7.07%
$ 5.0m
Samuel Berry
General Counsel & Corporate Secretary7.6yrsno datano data
7.6yrs
Average Tenure
54.5yo
Average Age

Experienced Management: FBIO's management team is seasoned and experienced (7.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Lindsay Rosenwald
Executive Chairman16.5yrsUS$1.38m14.39%
$ 10.2m
Michael Weiss
Executive Vice Chairman of Strategic Development & Director12.3yrsUS$1.23m7.07%
$ 5.0m
Malcolm Hoenlein
Independent Director12.2yrsUS$45.03k0.20%
$ 139.4k
Stephen Nimer
Scientific Advisor8.8yrsno datano data
Dov Klein
Independent Director10.8yrsUS$120.07k0.085%
$ 60.5k
William Sandborn
Scientific Advisor8.8yrsno datano data
J. Lobell
Independent Director19.8yrsUS$87.57k0.36%
$ 255.1k
David Elliott
Scientific Advisor8.8yrsno datano data
Joel Weinstock
Scientific Advisor8.8yrsno datano data
Mark Lowdell
Member of Scientific Advisory Boardno datano datano data
Jimmie Harvey
Independent Director17.3yrsUS$67.57k0.010%
$ 7.4k
Jeffrey Miller
Scientific Advisor8.8yrsno datano data
10.8yrs
Average Tenure
70yo
Average Age

Experienced Board: FBIO's board of directors are seasoned and experienced ( 10.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/30 09:16
End of Day Share Price 2026/04/29 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fortress Biotech, Inc. is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
Stephen V. ByrneBofA Global Research
Mayank MamtaniB. Riley Securities, Inc.